Human BioSciences, Inc. is a multinational biotechnology company that has been designing, manufacturing, distributing, and marketing a range of advanced collagen-based wound care products for almost thirty years. Therefore, Human BioSciences’ ability to convert laboratory concepts into exceptional and affordable advanced wound care products sets a higher standard for advanced wound care with products; SkinTemp® II, Medifil® II, and Collatek®. Our collagen products are carefully bioengineered with a proprietary Kollagen ™ technology to ensure collagen molecules retain bioactivity and keeping collagen in its purest form. Human BioSciences’ support the body’s natural healing process.
Our proprietary products contain Type 1 fibrillar bovine (cattle) derived native collagen including less than 5% water. This proprietary blend sets Human Biosciences’ apart from other collagen dressing technologies making it most analogous to human collagen. Collagen in its purest form binds and inactivates excessive MMPs, thus stimulating wounds through the healing trajectory.
Human Biosciences’ products are easy to use and are applied directly to the wound, thus delivering the body's one common denominator in healing – properly configured collagen. This eliminates the need for products dependent on wound stage, wound depth, or chemical growth factors. We offer various formulations of collagen including particles, sheets, and gel. Our quality products can be used on superficial, partial, and full-thickness wounds of all etiologies, excluding third-degree burns.
All products are FDA cleared, reimbursed by Medicare Part B, as well as other third-party payers. KollagenTM products are revolutionizing the wound care industry by reducing healing times, treatment costs, amputation rates, and wound recurrence.
Patient-centered care is essential in wound management. Therefore, our KollagenTM technology provides clinicians with “go-to” products to optimize healing outcomes while supporting the patient’s quality of life. Faster healing times reduce the risks of infection, amputation, and death. Human BioSciences takes pride in being a key leader in the advanced wound care product industry.
1600s Wound care focuses on maintaining a dry wound environment. Dressings such as cotton linters, paper, feathers, and dust are used.
1800s Caregivers use cotton gauze, knit fibers, nonwoven swabs, sleeve dressings, and adhesive paper.
1867 Lister introduces antiseptics.
1962 Winter's landmark study finds “moist wounds epithelialized more rapidly than dry wounds.”
1980s Hunt observes visible fibroblast activity in wounds within a couple of days of the injury. There is increasing awareness that dressings do more than protect the wound; they can influence the normal physiologic response to wounding.
1990s Outcome-based protocols require that clinicians define and compare which treatments or therapies work best, at what cost, and in what length of time.
1991 KollagenTM wound management technology is developed. KollagenTM based dressings follow moist wound healing principles and enhance the body's natural healing process.
1994 Continued research confirms that intact collagen plays a key role in wound healing.
Present Increased use of biocompatible and bioabsorbable materials. Dressings are delivery systems for active agents, growth factors, and debridement agents. This has resulted in a fragmented market that includes a variety of different products that produce similar inconsistent results. KollagenTM technology remains unmatched in its ability to deliver consistent positive outcomes.